Immune checkpoint inhibitors combined with chemotherapy/antiangiogenic therapy for heavily treated advanced lung cancer patients with EGFR mutation: a retrospective analysis

Ran Hu<sup>1</sup>, Zhiting Zhao<sup>1</sup>, Yue Shi<sup>1</sup>, Meiqi Shi<sup>1</sup>, Guohao Xia<sup>1</sup>, Shaorong Yu<sup>1</sup>, and Jifeng Feng<sup>2</sup>

September 21, 2020

Immune checkpoint inhibitors combined with chemotherapy/antiangiogenic therapy for heavily treated advanced lung cancer patients with EGFR mutation: a retrospective analysis

Anti-PD-1/PD-L1 therapy combined with chemotherapy/antiangiogenic therapy for EGFR-mutated lung cancer patients: a retrospective analysis

Ran Hu<sup>1\*</sup>, Zhiting Zhao<sup>1\*</sup>, Yue Shi<sup>1</sup>, Meiqi Shi<sup>1</sup>, Guohao Xia<sup>1</sup>, Shaorong Yu<sup>1</sup>, Jifeng Feng<sup>1</sup>

Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu Province, China.

\* These authors have contributed equally to this work.

Conflict of Interest : None.

Acknowledgments : None.

Keywords: EGFR, mutation, lung adenocarcinoma, PD-1, chemotherapy

Hosted file

manuscript.docx available at https://authorea.com/users/360004/articles/481752-immune-checkpoint-inhibitors-combined-with-chemotherapy-antiangiogenic-therapy-for-heavily-treated-advanced-lung-cancer-patients-with-egfr-mutation-a-retrospective-analysis

<sup>&</sup>lt;sup>1</sup>Jiangsu Cancer Hospital

<sup>&</sup>lt;sup>2</sup>Affiliation not available

Figure 1





Figure 2



## Hosted file

Table 1 -  $\ensuremath{\mbox{begin{CJK}{gbsn}.\end{CJK}\selectlanguage{english}}\docx available at https://authorea.com/users/360004/articles/481752-immune-checkpoint-inhibitors-combined-with-chemotherapy-antiangiogenic-therapy-for-heavily-treated-advanced-lung-cancer-patients-with-egfr-mutation-a-retrospective-analysis}$ 

## Hosted file

 $\label{thm:com/users/360004/articles/481752-immune-checkpoint-inhibitors-combined-with-chemotherapy-antiangiogenic-therapy-for-heavily-treated-advanced-lung-cancer-patients-with-egfr-mutation-a-retrospective-analysis$